Reduction of UPDRS scores and significances (Wilcoxon-Mann-Whitney) for the ITT population (LOCF)
| Pramipexole (n=33) | Placebo (n=44) | p Value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean change (SD) | Mean % change | Median change | Mean change (SD) | Mean % change | Median change | ||||
| UPDRS total score | 20.1 (16.0) | 37.3 | 20.0 | 5.9 (12.8) | 13.1 | 5.25 | 0.0002 | ||
| UPDRS part I | 0.7 (1.6) | 27.0 | 0.0 | −0.1 (1.0) | −1.0 | 0.0 | 0.1282-150 | ||
| UPDRS part II | 4.4 (4.7) | 32.2 | 4.0 | 1.1 (3.4) | 7.5 | 1.0 | 0.0034 | ||
| UPDRS part III | 13.2 (11.0) | 39.4 | 14.0 | 4.5 (9.5) | 15.3 | 5.0 | 0.0008 | ||
| UPDRS part IV | 1.8 (2.6) | 23.2 | 1.0 | 0.4 (2.1) | 1.2 | 0.0 | 0.0092 | ||
↵2-150 χ2 test for categories “improved; unchanged; deteriorated”.